A forum for researchers, students and applicants in the field of cyclodextrin technology
Beren Therapeutics Announced FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C. Beren Therapeutics
JIC Venture Growth Investments (VGI) announced that it has invested in Beren Therapeutics P.B.C. (“Beren Therapeutics”). Beren Therapeutics is developing
Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick
Rafael Holdings and Cyclo Therapeutics on Thursday announced a merger agreement as they look to spur development of their Niemann-Pick
This study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially
Niemann–Pick Type C (NPC) represents an autosomal recessive disorder with an incidence rate of 1 in 150,000 live births, classified
Cyclo Therapeutics, (Cyclo) a clinical stage company focused on developing therapies for rare and neurological diseases with limited treatment options,
This work presents the most recent advances in the research and clinical use of HPβCD against Niemann–Pick disease, a congenital
The Pulitzer Prize-winning Wall Street Journal science- and health writer, Amy Dockser Marcus, in her new book „We the Scientists”
RENATUS, a South Korea-based pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases recently filed
